MicroRNA-specific regulatory mechanisms in atherosclerosis

Journal of Molecular and Cellular Cardiology

Volumn 89, Issue , 2015, Pages 35-41

  Nazari Jahantigh, Maliheh ^a   Egea, Virginia ^a   Schober, Andreas ^a,b   Weber, Christian ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Atherosclerosis; MicroRNAs

Indexed keywords

LIPOPROTEIN; MICRORNA;

ATHEROSCLEROSIS; CELL ACTIVATION; CELL COMMUNICATION; CELL REGENERATION; ENDOTHELIUM; HUMAN; MACROPHAGE; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RNA TRANSPORT; ANIMAL; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MACROPHAGE ACTIVATION; MICRORNAS; MODELS, BIOLOGICAL;

EID: 84952674396     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.10.021     Document Type: Review

References (99)

1. Nam D., Ni C.W., Rezvan A., Suo J., Budzyn K., Llanos A., et al. Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. Am J Physiol Heart Circ Physiol 2009, 297:H1535-H1543.
2. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011, 17:1410-1422.
3. Dekker R.J., Boon R.A., Rondaij M.G., Kragt A., Volger O.L., Elderkamp Y.W., et al. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood 2006, 107:4354-4363.
4. Ni C.W., Qiu H., Rezvan A., Kwon K., Nam D., Son D.J., et al. Discovery of novel mechanosensitive genes in vivo using mouse carotid artery endothelium exposed to disturbed flow. Blood 2010, 116:e66-e73.
5. Berk B.C. Atheroprotective signaling mechanisms activated by steady laminar flow in endothelial cells. Circulation 2008, 117:1082-1089.
6. Cuchel M., Rader D.J. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. Circulation 2006, 113:2548-2555.
7. Rayner K.J., Fernandez-Hernando C., Moore K.J. MicroRNAs regulating lipid metabolism in atherogenesis. Thromb Haemost 2012, 107:642-647.
8. Ha M., Kim V.N. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014, 15:509-524.
9. Helwak A., Kudla G., Dudnakova T., Tollervey D. Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell 2013, 153:654-665.
10. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
11. Arvey A., Larsson E., Sander C., Leslie C.S., Marks D.S. Target mRNA abundance dilutes microRNA and siRNA activity. Mol Syst Biol 2010, 6:363.
12. Garcia D.M., Baek D., Shin C., Bell G.W., Grimson A., Bartel D.P. Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol 2011, 18:1139-1146.
13. Salmena L., Poliseno L., Tay Y., Kats L., Pandolfi P.P. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell 2011, 146:353-358.
14. Tay Y., Rinn J., Pandolfi P.P. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014, 505:344-352.
15. Hansen T.B., Jensen T.I., Clausen B.H., Bramsen J.B., Finsen B., Damgaard C.K., et al. Natural RNA circles function as efficient microRNA sponges. Nature 2013, 495:384-388.
16. Memczak S., Jens M., Elefsinioti A., Torti F., Krueger J., Rybak A., et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013, 495:333-338.
17. Poliseno L., Salmena L., Zhang J., Carver B., Haveman W.J., Pandolfi P.P. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010, 465:1033-1038.
18. Denzler R., Agarwal V., Stefano J., Bartel D.P., Stoffel M. Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance. Mol Cell 2014, 54:766-776.
19. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
20. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
21. Matranga C., Tomari Y., Shin C., Bartel D.P., Zamore P.D. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 2005, 123:607-620.
22. Rand T.A., Petersen S., Du F., Wang X. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 2005, 123:621-629.
23. Kang S.M., Choi J.W., Hong S.H., Lee H.J. Up-Regulation of microRNA* Strands by Their Target Transcripts. Int J Mol Sci 2013, 14:13231-13240.
24. Ro S., Park C., Young D., Sanders K.M., Yan W. Tissue-dependent paired expression of miRNAs. Nucleic Acids Res 2007, 35:5944-5953.
25. Chiang H.R., Schoenfeld L.W., Ruby J.G., Auyeung V.C., Spies N., Baek D., et al. Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. Genes Dev 2010, 24:992-1009.
26. Czech B., Zhou R., Erlich Y., Brennecke J., Binari R., Villalta C., et al. Hierarchical rules for Argonaute loading in Drosophila. Mol Cell 2009, 36:445-456.
27. Marco A., Macpherson J.I., Ronshaugen M., Griffiths-Jones S. MicroRNAs from the same precursor have different targeting properties. Silence 2012, 3:8.
28. Sakurai K., Furukawa C., Haraguchi T., Inada K., Shiogama K., Tagawa T., et al. MicroRNAs miR-199a-5p and -3p target the Brm subunit of SWI/SNF to generate a double-negative feedback loop in a variety of human cancers. Cancer Res 2011, 71:1680-1689.
29. Zhang Y., Yang P., Sun T., Li D., Xu X., Rui Y., et al. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol 2013, 15:284-294.
30. Uchino K., Takeshita F., Takahashi R.U., Kosaka N., Fujiwara K., Naruoka H., et al. Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression. Mol Ther 2013, 21:610-619.
31. Yang X., Du W.W., Li H., Liu F., Khorshidi A., Rutnam Z.J., et al. Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Res 2013, 41:9688-9704.
32. Almeida M.I., Nicoloso M.S., Zeng L., Ivan C., Spizzo R., Gafa R., et al. Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. Gastroenterology 2012, 142:886-896. e9.
33. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
34. Bang C., Batkai S., Dangwal S., Gupta S.K., Foinquinos A., Holzmann A., et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest 2014, 124:2136-2146.
35. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
36. Kosaka N., Iguchi H., Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010, 101:2087-2092.
37. Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010, 56:1733-1741.
38. Etheridge A., Lee I., Hood L., Galas D., Wang K. Extracellular microRNA: a new source of biomarkers. Mutat Res 2011, 717:85-90.
39. Fichtlscherer S., Zeiher A.M., Dimmeler S. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?. Arterioscler Thromb Vasc Biol 2011, 31:2383-2390.
40. Creemers E.E., Tijsen A.J., Pinto Y.M. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?. Circ Res 2012, 110:483-495.
41. Kosaka N., Iguchi H., Yoshioka Y., Takeshita F., Matsuki Y., Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010, 285:17442-17452.
42. Vickers K.C., Remaley A.T. Lipid-based carriers of microRNAs and intercellular communication. Curr Opin Lipidol 2012, 23:91-97.
43. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011.
44. Villarroya-Beltri C., Gutierrez-Vazquez C., Sanchez-Cabo F., Perez-Hernandez D., Vazquez J., Martin-Cofreces N., et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun 2013, 4:2980.
45. Zernecke A., Bidzhekov K., Noels H., Shagdarsuren E., Gan L., Denecke B., et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009, 2:ra81.
46. Hergenreider E., Heydt S., Treguer K., Boettger T., Horrevoets A.J., Zeiher A.M., et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 2012, 14:249-256.
47. Boettger T., Beetz N., Kostin S., Schneider J., Kruger M., Hein L., et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009, 119:2634-2647.
48. Wolfs I.M., Donners M.M., de Winther M.P. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost 2011, 106:763-771.
49. Murray P.J., Allen J.E., Biswas S.K., Fisher E.A., Gilroy D.W., Goerdt S., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014, 41:14-20.
50. Locati M., Mantovani A., Sica A. Macrophage activation and polarization as an adaptive component of innate immunity. Adv Immunol 2013, 120:163-184.
51. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581.
52. Curtale G., Mirolo M., Renzi T.A., Rossato M., Bazzoni F., Locati M. Negative regulation of Toll-like receptor 4 signaling by IL-10-dependent microRNA-146b. Proc Natl Acad Sci U S A 2013, 110:11499-11504.
53. Ma X., Becker Buscaglia L.E., Barker J.R., Li Y. MicroRNAs in NF-kappaB signaling. J Mol Cell Biol 2011, 3:159-166.
54. O'Connell R.M., Rao D.S., Chaudhuri A.A., Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010, 10:111-122.
55. Nazari-Jahantigh M., Wei Y., Noels H., Akhtar S., Zhou Z., Koenen R.R., et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest 2012, 122:4190-4202.
56. Graff J.W., Dickson A.M., Clay G., McCaffrey A.P., Wilson M.E. Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem 2012, 287:21816-21825.
57. Koch M., Mollenkopf H.J., Klemm U., Meyer T.F. Induction of microRNA-155 is TLR- and type IV secretion system-dependent in macrophages and inhibits DNA-damage induced apoptosis. Proc Natl Acad Sci U S A 2012, 109:E1153-E1162.
58. O'Connell R.M., Taganov K.D., Boldin M.P., Cheng G., Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A 2007, 104:1604-1609.
59. Quinn S.R., Mangan N.E., Caffrey B.E., Gantier M.P., Williams B.R., Hertzog P.J., et al. The role of Ets2 transcription factor in the induction of microRNA-155 (miR-155) by lipopolysaccharide and its targeting by interleukin-10. J Biol Chem 2014, 289:4316-4325.
60. Tian F.J., An L.N., Wang G.K., Zhu J.Q., Li Q., Zhang Y.Y., et al. Elevated microRNA-155 promotes foam cell formation by targeting HBP1 in atherogenesis. Cardiovasc Res 2014, 103:100-110.
61. Androulidaki A., Iliopoulos D., Arranz A., Doxaki C., Schworer S., Zacharioudaki V., et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009, 31:220-231.
62. Guha M., Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002, 277:32124-32132.
63. Arranz A., Doxaki C., Vergadi E., Martinez de la Torre Y., Vaporidi K., Lagoudaki E.D., et al. Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc Natl Acad Sci U S A 2012, 109:9517-9522.
64. Wei Y., Nazari-Jahantigh M., Chan L., Zhu M., Heyll K., Corbalan-Campos J., et al. The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. Circulation 2013, 127:1609-1619.
65. Nazari-Jahantigh M., Wei Y., Schober A. The role of microRNAs in arterial remodelling. Thromb Haemost 2012, 107:611-618.
66. Du F., Yu F., Wang Y., Hui Y., Carnevale K., Fu M., et al. MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2014, 34:759-767.
67. Aiello R.J., Bourassa P.A., Lindsey S., Weng W., Natoli E., Rollins B.J., et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1999, 19:1518-1525.
68. Wei Y., Schober A., Weber C. Pathogenic arterial remodeling: the good and bad of microRNAs. Am J Physiol Heart Circ Physiol 2013, 304:H1050-H1059.
69. Donners M.M., Wolfs I.M., Stoger L.J., van der Vorst E.P., Pottgens C.C., Heymans S., et al. Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One 2012, 7:e35877.
70. Fish J.E., Santoro M.M., Morton S.U., Yu S., Yeh R.F., Wythe J.D., et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008, 15:272-284.
71. Wang S., Aurora A.B., Johnson B.A., Qi X., McAnally J., Hill J.A., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008, 15:261-271.
72. Harris T.A., Yamakuchi M., Ferlito M., Mendell J.T., Lowenstein C.J. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A 2008, 105:1516-1521.
73. Neth P., Nazari-Jahantigh M., Schober A., Weber C. MicroRNAs in flow-dependent vascular remodelling. Cardiovasc Res 2013, 99:294-303.
74. Schober A., Nazari-Jahantigh M., Wei Y., Bidzhekov K., Gremse F., Grommes J., et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 2014, 20:368-376.
75. Rodriguez P., Higueras M.A., Gonzalez-Rajal A., Alfranca A., Fierro-Fernandez M., Garcia-Fernandez R.A., et al. The non-canonical NOTCH ligand DLK1 exhibits a novel vascular role as a strong inhibitor of angiogenesis. Cardiovasc Res 2012, 93:232-241.
76. Baladron V., Ruiz-Hidalgo M.J., Nueda M.L., Diaz-Guerra M.J., Garcia-Ramirez J.J., Bonvini E., et al. dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats. Exp Cell Res 2005, 303:343-359.
77. Falix F.A., Aronson D.C., Lamers W.H., Gaemers I.C. Possible roles of DLK1 in the Notch pathway during development and disease. Biochim Biophys Acta 2012, 1822:988-995.
78. Jansen F., Yang X., Hoelscher M., Cattelan A., Schmitz T., Proebsting S., et al. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 2013, 128:2026-2038.
79. Bartling B., Tostlebe H., Darmer D., Holtz J., Silber R.E., Morawietz H. Shear stress-dependent expression of apoptosis-regulating genes in endothelial cells. Biochem Biophys Res Commun 2000, 278:740-746.
80. Zeng L., Zampetaki A., Margariti A., Pepe A.E., Alam S., Martin D., et al. Sustained activation of XBP1 splicing leads to endothelial apoptosis and atherosclerosis development in response to disturbed flow. Proc Natl Acad Sci U S A 2009, 106:8326-8331.
81. Foteinos G., Hu Y., Xiao Q., Metzler B., Xu Q. Rapid endothelial turnover in atherosclerosis-prone areas coincides with stem cell repair in apolipoprotein E-deficient mice. Circulation 2008, 117:1856-1863.
82. Chu J., Sadler K.C. New school in liver development: lessons from zebrafish. Hepatology 2009, 50:1656-1663.
83. Hong D., Bai Y.P., Gao H.C., Wang X., Li L.F., Zhang G.G., et al. Ox-LDL induces endothelial cell apoptosis via the LOX-1-dependent endoplasmic reticulum stress pathway. Atherosclerosis 2014, 235:310-317.
84. Civelek M., Manduchi E., Riley R.J., Stoeckert C.J., Davies P.F. Chronic endoplasmic reticulum stress activates unfolded protein response in arterial endothelium in regions of susceptibility to atherosclerosis. Circ Res 2009, 105:453-461.
85. Itoh Y., Toriumi H., Yamada S., Hoshino H., Suzuki N. Resident endothelial cells surrounding damaged arterial endothelium reendothelialize the lesion. Arterioscler Thromb Vasc Biol 2010, 30:1725-1732.
86. Chen C.H., Jiang W., Via D.P., Luo S., Li T.R., Lee Y.T., et al. Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation 2000, 101:171-177.
87. Loyer X., Potteaux S., Vion A.C., Guerin C.L., Boulkroun S., Rautou P.E., et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res 2014, 114:434-443.
88. Sun X., He S., Wara A.K., Icli B., Shvartz E., Tesmenitsky Y., et al. Systemic delivery of microRNA-181b inhibits nuclear factor-kappaB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res 2014, 114:32-40.
89. Poissonnier L., Villain G., Soncin F., Mattot V. miR126-5p repression of ALCAM and SetD5 in endothelial cells regulates leucocyte adhesion and transmigration. Cardiovasc Res 2014, 102:436-447.
90. Akhtar S., Gremse F., Kiessling F., Weber C., Schober A. CXCL12 promotes the stabilization of atherosclerotic lesions mediated by smooth muscle progenitor cells in Apoe-deficient mice. Arterioscler Thromb Vasc Biol 2013, 33:679-686.
91. Kuhlmann C.R., Schaefer C.A., Reinhold L., Tillmanns H., Erdogan A. Signalling mechanisms of SDF-induced endothelial cell proliferation and migration. Biochem Biophys Res Commun 2005, 335:1107-1114.
92. Wei Y., Nazari-Jahantigh M., Neth P., Weber C., Schober A. MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis?. Arterioscler Thromb Vasc Biol 2013, 33:449-454.
93. Fichtlscherer S., De Rosa S., Fox H., Schwietz T., Fischer A., Liebetrau C., et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010, 107:677-684.
94. Zampetaki A., Kiechl S., Drozdov I., Willeit P., Mayr U., Prokopi M., et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010, 107:810-817.
95. Mocharla P., Briand S., Giannotti G., Dorries C., Jakob P., Paneni F., et al. AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: role for proangiogenic effects and alterations in type 2 diabetics. Blood 2013, 121:226-236.
96. Zhou J., Li Y.S., Nguyen P., Wang K.C., Weiss A., Kuo Y.C., et al. Regulation of vascular smooth muscle cell turnover by endothelial cell-secreted microRNA-126: role of shear stress. Circ Res 2013, 113:40-51.
97. Wagner J., Riwanto M., Besler C., Knau A., Fichtlscherer S., Roxe T., et al. Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. Arterioscler Thromb Vasc Biol 2013, 33:1392-1400.
98. Besler C., Heinrich K., Rohrer L., Doerries C., Riwanto M., Shih D.M., et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011, 121:2693-2708.
99. Janas T., Yarus M. Specific RNA binding to ordered phospholipid bilayers. Nucleic Acids Res 2006, 34:2128-2136.